(:DBTX)

Sep 18, 2023 04:59 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, RETA, VRTV, HCCI
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Sep 12, 2023 06:46 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, CPRI, CEQP, ESTE
NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 12, 2023 02:01 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, CELL, CCF, AGE
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Sep 07, 2023 10:36 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SOVO, DBTX, DM, ZYNE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sovos Brands, Inc. (NASDAQ: SOVO)’s...
Sep 07, 2023 10:15 am ET
Moore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Sep 05, 2023 07:46 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – NEWR, AMNB, DBTX, RETA
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Sep 05, 2023 11:21 am ET
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Decibel Therapeutics, Inc. (NasdaqGS: DBTX) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Decibel will receive only $4.00 in cash for each share of Decibel that they own, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones. KSF is seeking to determine
Aug 31, 2023 10:32 am ET
Moore Kuehn Encourages CTG, KLR, ZYNE, and DBTX Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Aug 31, 2023 08:54 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Aug 29, 2023 12:34 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc. (NASDAQ:...
Aug 29, 2023 11:47 am ET
Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Aug 28, 2023 05:34 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, CELL, ESTE, CPRI
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 24, 2023 12:17 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sovos Brands, Inc. (Nasdaq - SOVO), Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Computer Task Group, Incorpo
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Aug 23, 2023 04:15 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRTV, DBTX, CPRI, AVID
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Veritiv Corporation (NYSE: VRTV)’s...
Aug 22, 2023 01:30 pm ET
Moore Kuehn Encourages DBTX, AVID, CPRI, and ARCE Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Aug 21, 2023 05:32 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CELL, DBTX, CPRI, ESTE
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 15, 2023 10:37 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Aug 14, 2023 06:00 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CPRI, ZYNE, APGN, DBTX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 12, 2023 08:17 pm ET
Lifshitz Law PLLC Announces Investigations of WMC, MITT, DBTX, and CTG
Western Asset Mortgage Capital Corporation (NYSE: WMC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc. Under the terms of the proposed...
Aug 12, 2023 12:45 pm ET
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Decibel Therapeutics, Inc. (NasdaqGS: DBTX) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Decibel will receive only $4.00 in cash for each share of Decibel that they own, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones. KSF is seeking to determine
Aug 11, 2023 12:11 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, DBTX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Computer Task Group, Inc. (NASDAQ:...
Aug 11, 2023 07:45 am ET
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended...
Aug 09, 2023 10:22 am ET
DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. (NASDAQ: DBTX) to Regeneron Pharmaceuticals, Inc. is fair to Decibel shareholders. Under the merger, Decibel shareholders will receive $4.00 per share in cash and a non-tradeable contingent value right entitling such holders to receive up to $3.50 per share in cash if certain clinical development and regulatory milestones are achieved.
Aug 09, 2023 09:31 am ET
DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals
The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right (“CVR”) for up to $3.50 per share in cash, pursuant to which Decibel Therapeutics, Inc. (Nasdaq: DBTX) (“Decibel”) has...
Aug 09, 2023 09:13 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Aug 09, 2023 07:30 am ET
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today...
Jul 10, 2023 09:31 am ET
Thinking about buying stock in Near Intelligence, Kineta, Greenidge Generation, FMC, or Decibel Therapeutics?
NEW YORK, July 10, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIR, KA, GREE, FMC, and DBTX.
Jun 02, 2023 07:00 am ET
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Jun 01, 2023 04:30 pm ET
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society...
May 31, 2023 11:20 am ET
Thinking about buying stock in Krystal Biotech, Axsome Therapeutics, 89bio, Scpharmaceuticals, or Decibel Therapeutics?
NEW YORK, May 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KRYS, AXSM, ETNB, SCPH, and DBTX.
May 17, 2023 04:30 pm ET
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
May 15, 2023 07:45 am ET
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended...
May 12, 2023 07:00 am ET
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application...
May 10, 2023 04:30 pm ET
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society...
Mar 30, 2023 07:00 am ET
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the European Medicines Agency (EMA)...
Mar 28, 2023 04:30 pm ET
Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Mar 21, 2023 07:00 am ET
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its...
Mar 14, 2023 04:05 pm ET
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and...
Feb 16, 2023 07:00 am ET
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Feb 09, 2023 07:00 am ET
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug...
Jan 24, 2023 07:00 am ET
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced authorization of its Clinical Trial...
Nov 09, 2022 04:44 pm ET
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended...
Nov 02, 2022 07:00 am ET
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of Clinical Trial...
Oct 17, 2022 07:00 am ET
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has received clearance from the U.S....
Oct 12, 2022 07:00 am ET
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its...
Sep 22, 2022 07:00 am ET
Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Sep 20, 2022 07:00 am ET
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the submission of an Investigational New Drug...
Aug 31, 2022 07:00 am ET
Decibel Therapeutics to Participate in Upcoming Investor Conferences
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Aug 10, 2022 04:30 pm ET
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended...
Jun 28, 2022 07:00 am ET
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim...
Jun 03, 2022 07:30 am ET
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and...
May 17, 2022 07:30 am ET
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
May 12, 2022 07:30 am ET
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended...
May 02, 2022 07:30 am ET
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present at the American Society...
Mar 22, 2022 07:30 am ET
Decibel Therapeutics to Participate in Upcoming Investor Conferences
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Mar 18, 2022 07:00 am ET
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
BOSTON, March 18, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported...
Feb 10, 2022 04:30 pm ET
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Feb 09, 2022 06:00 pm ET
Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Ac
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced the presentation of preclinical data on its lead...
Jan 31, 2022 07:00 am ET
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug...
Jan 04, 2022 07:00 am ET
Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Dec 06, 2021 07:30 am ET
Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointments of Alison Finger, MBA and...
Nov 22, 2021 07:30 am ET
Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Regeneron has extended the research term...
Nov 10, 2021 07:30 am ET
Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended...
Nov 08, 2021 07:00 am ET
Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays...
Oct 20, 2021 07:30 am ET
Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Sep 30, 2021 05:42 pm ET
Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from a study of noise-related...
Sep 09, 2021 07:30 am ET
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug...
Sep 02, 2021 07:30 am ET
Decibel Therapeutics to Present at Upcoming Investor Conferences
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the Company will participate in the...
Aug 18, 2021 07:30 am ET
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Cynthia Hu, J.D., as Chief...
Aug 10, 2021 07:30 am ET
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended...
Jun 02, 2021 08:30 am ET
Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of Directors
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of William (Bill) H. Carson,...
May 24, 2021 04:15 pm ET
Decibel Therapeutics Expands World-Class Scientific Advisory Board
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of leading experts in gene...
May 19, 2021 08:00 am ET
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
May 13, 2021 05:05 pm ET
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended...
Apr 28, 2021 08:00 am ET
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present two digital presentations...
Apr 08, 2021 08:00 am ET
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive...
Mar 29, 2021 04:05 pm ET
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and...
Mar 22, 2021 08:00 am ET
Decibel Therapeutics Added to Russell 2000 Index
Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the...
Mar 04, 2021 08:00 am ET
Decibel Therapeutics to Present at the Barclays Global Healthcare Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that Laurence Reid, Ph.D., Chief Executive...
Feb 24, 2021 07:00 am ET
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data supporting the company’s gene therapy product candidate, DB-OTO, a potential transformative...
Feb 19, 2021 07:00 am ET
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug...
Feb 11, 2021 09:51 pm ET
Decibel Therapeutics Announces Pricing of Initial Public Offering
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.